- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Drug pipeline for women's health to see growth
There are 373 new prescription medicines for women in the drug pipeline, according to a recent survey of 144 companies released by the Pharmaceutical Research and Manufacturers of America.
There are 373 new prescription medicines for women in the drug pipeline, according to a recent survey of 144 companies released by the Pharmaceutical Research and Manufacturers of America.
Researchers are attacking six primary diseases: arthritis, osteoporosis, heart disease, stroke, lung cancer and breast cancer.
Arthritis affects 23 million women in the United States, costing the U.S. economy nearly $65 billion each year, according to PhRMA. Pharmaceutical companies are researching 55 new products to treat the condition, including a new class of drugs known as selective COX-2 inhibitors.
Osteoporosis affects one in four women and results in more than 1.3 million hip fractures per year. The Alliance for Aging Research estimates the annual cost of the condition to be $10 million. At least one of 27 new products for osteoporosis has the potential to build bone mass by up to 10%, PhRMA stated.
More than half of American deaths caused by heart disease and stroke occur in women. Although more men suffer strokes, more women die from them, and 44% of women who have heart attacks die, compared with only 27% of men. PhRMA's survey revealed that there are 48 new medicines in the drug pipeline for cardiovascular illness.
But pharmaceutical companies have devoted the greatest research and development energy to finding treatments for breast and lung cancers. Breast cancer affects 8 million American women and costs $10 billion per year. Lung cancer - the leading cause of cancer death among women, according to the American Cancer Society - kills an estimated 66,000 women annually.
PhRMA found that 109 products are being developed to battle breast and lung cancer. PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
